Vivek Y. Reddy et al. JACEP 2019;j.jacep

Slides:

Advertisements

Similar presentations

SMASH-VT Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Vivek Reddy Substrate Mapping and Ablation in Sinus Rhythm to Halt.

Advertisements

Widimsky P, Tousek P, Rokyta R, et al. Charles University Prague, CZ PRAGUE-7 Study (Hot Lines presenter)

Ablation for Paroxysmal Atrial Fibrillation (APAF) Trial Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Carlo.

Amr Kamal, M.D Alexandria Main University Hospital Alexandria- Egypt ECRA 2010.

©2012 MFMER | slide-1 New methods and techniques in catheter ablation of atrial fibrillation Yong-Mei Cha, MD Mayo Clinic NCF Shenyang, 2014.

Barts and The London NHS Trust NHS Barts and The London NHS Trust NHS AF ablations at SBH August 2008 – August 2009 Patients undergoing first ablation.

Feasibility & Safety of Dabigatran vs Warfarin for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation:

A-4 Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Pierre Jais Atrial Fibrillation Ablation vs. Antiarrhythmic Drugs Trial.

One year follow-up after cryoballoon isolation of the pulmonary veins in patients with paroxysmal atrial fibrillation by Yves Van Belle, Petter Janse,

Catheter Ablation of Atrial Fibrillation by Roderick Tung, Eric Buch, and Kalyanam Shivkumar Circulation Volume 126(2): July 10, 2012 Copyright.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comparison of Radiofrequency Catheter Ablation of.

Radiofrequency Ablation as Initial Therapy in Paroxysmal Atrial Fibrillation Jens Cosedis Nielsen, M.D., D.M.Sc., Arne Johannessen, M.D., D.M.Sc., Pekka.

Rationale and design of the FreezeAF trial: A randomized controlled noninferiority trial comparing isolation of the pulmonary veins with the cryoballoon.

Figure 1 Pulmonary vein anatomical locations

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

RE-CIRCUIT Trial design: Patients with atrial fibrillation undergoing catheter ablation were randomized to uninterrupted dabigatran 150 mg twice daily.

Michala E.F. Pedersen et al. JACEP 2017;3:

Volume 11, Issue 1, Pages (January 2014)

Overall burden of AF associated with higher risk of thromboembolism and ischemic stroke An analysis of the KP-RHYTHM study, in patients with paroxysmal.

(p for noninferiority = )

Saurabh Kumar et al. JACEP 2017;3:

MAGIC-AF Trial design: Patients with persistent atrial fibrillation (AF) and remaining in AF after pulmonary vein isolation alone were randomized to either.

Endothelial Dysfunction in Patients With Lone AF and AF Patients With Comorbidities Compared With That in Controls Comparisons are shown among control.

Waddah Maskoun et al. JACEP 2016;2:

Catheter Ablation for the Cure of Atrial Fibrillation Study

Shadi Al Halabi et al. JACEP 2015;1:

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Jong Sung Park et al. JACEP 2016;2:

Pablo B. Nery et al. JACEP 2016;2:

Sébastien P.J. Krul et al. JACEP 2015;1:

Superiority of cut-and-sew technique for the Cox maze procedure: Comparison with radiofrequency ablation John M. Stulak, MD, Joseph A. Dearani, MD, Thoralf.

AFACT Trial design: Patients with long-standing atrial fibrillation were randomized to ganglion plexus ablation (n = 117) vs. control (n = 123) on top.

Dhanunjaya Lakkireddy et al. JACEP 2015;1:

Sigfus Gizurarson et al. JACEP 2016;2:

Junaid A.B. Zaman et al. JACEP 2017;3:

Risk Factor Modification

Amir Jadidi et al. JACEP 2018;4:

Michala E.F. Pedersen et al. JACEP 2016;j.jacep

Shohreh Honarbakhsh et al. JACEP 2017;j.jacep

Stavros Stavrakis et al. JACEP 2015;1:1-13

FDA Perspective Marco Cannella, PhD Senior Lead Reviewer

Moussa Mansour et al. JACEP 2017;3:

Vittorio Calzolari et al. JACEP 2017;3:

Konstantinos C. Siontis et al. JACEP 2016;2:

Hematemesis in a Patient Presenting With Right-Sided Weakness and Recent Percutaneous Catheter Radiofrequency Ablation for Atrial Fibrillation Ming-Hsi.

Pouria Alipour et al. JACEP 2017;j.jacep

The procedural journey for our cohort of patients with persistent atrial fibrillation. The procedural journey for our cohort of patients with persistent.

Brian D. Williamson et al. JACEP 2017;3:

Philippe Taghji et al. JACEP 2017;j.jacep

Vivek Y. Reddy et al. JACEP 2016;2:

Anna Björkenheim et al. JACEP 2017;j.jacep

Henry Chubb et al. JACEP 2017;3:89-103

Eran Leshem et al. JACEP 2018;j.jacep

Moussa Mansour et al. JACEP 2016;j.jacep

Anna Björkenheim et al. JACEP 2017;j.jacep

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

Bernard Lim et al. JACEP 2016;2:

Eran Leshem et al. JACEP 2017;j.jacep

Jose C. Pachon M. et al. JACEP 2015;1:

Anna Björkenheim et al. JACEP 2017;j.jacep

Nat. Rev. Cardiol. doi: /nrcardio

Duy T. Nguyen et al. JACEP 2017;3:

Left Atrial Appendage Occlusion for The Unmet Clinical Needs of Stroke Prevention in Nonvalvular Atrial Fibrillation David R. Holmes, MD, Mohamad Alkhouli,

Overall burden of AF associated with higher risk of thromboembolism and ischemic stroke An analysis of the KP-RHYTHM study, in patients with paroxysmal.

Fehmi Keçe et al. JACEP 2018;j.jacep

Illustration of a trial design to help evaluate the clinical accuracy of a test of ischaemia. Illustration of a trial design to help evaluate the clinical.

Vivek Y. Reddy et al. JACEP 2019;j.jacep

Waqas Ullah et al. JACEP 2017;j.jacep

Forest plot of all-cause mortality (ACM) in CRT patient with AF comparing atrioventricular junction ablation (AVJA) versus no AVJA. AF, atrial fibrillation;

Temporal trends of AF hospitalisation per 100 patients with AF according to main hospitalisation causes between 2006 and *P value for increase trends

Presentation transcript:

Vivek Y. Reddy et al. JACEP 2019;j.jacep.2019.04.009 Procedural Parameters in the QDOT-FAST Study Key procedural parameters are shown for both the first-in-man QDOT-FAST (Clinical Study for Safety and Acute Performance Evaluation of the THERMOCOOL SMARTTOUCH SF-5D System Used With Fast Ablation Mode in Treatment of Patients With Paroxysmal Atrial Fibrillation) trial, as well as previous multicenter studies: the THERMOCOOL AF (THERMOCOOL SMARTTOUCH Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation) trial, which investigated a saline-irrigated RF ablation catheter (3); the SMART AF (THERMOCOOL SMARTTOUCH Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation) trial, which investigated a saline-irrigated force-sensing ablation catheter (4); and the SMART-SF (SMART SF Radiofrequency Ablation Safety Study) trial, which investigated a force-sensing ablation catheter with enhanced saline irrigation (8). *Note: Procedure time included 20-min waiting period. RF = radiofrequency. Vivek Y. Reddy et al. JACEP 2019;j.jacep.2019.04.009 2019 The Authors